The mGlu5 positive allosteric modulator LSN2463359 differentially modulates motor, instrumental and cognitive effects of NMDA receptor antagonists in the rat

Neuropharmacology

Volumn 64, Issue , 2013, Pages 240-247

  Gastambide, Francois ^a   Gilmour, Gary ^a   Robbins, Trevor W ^b   Tricklebank, Mark D ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UK   (United Kingdom)

Author keywords

Behaviour; Glutamate; mGlu5 receptor; NMDA receptor antagonist; Potentiator; Psychosis; Reversal learning; Schizophrenia

Indexed keywords

1 [2 (4 HYDROXYPHENOXY)ETHYL] 4 (4 METHYLBENZYL)PIPERIDIN 4 OL; ALPHA AMINO 2' CHLORO 5 (PHOSPHONOMETHYL)(1,1' BIPHENYL) 3 PROPANOIC ACID; DIZOCILPINE; LSN 2463359; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; N (1 METHYLETHYL) 5 (PYRIDIN 4 YLETHYNYL)PYRIDINE 2 CARBOXAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; LEARNING; LOCOMOTION; MALE; MENTAL TASK; MOTOR PERFORMANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; REWARD;

ALLOSTERIC REGULATION; ANIMALS; BEHAVIOR, ANIMAL; COGNITION; COGNITION DISORDERS; DISCRIMINATION LEARNING; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MOLECULAR TARGETED THERAPY; MOTOR ACTIVITY; NOOTROPIC AGENTS; PSYCHOMOTOR DISORDERS; PYRIDINES; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; REVERSAL LEARNING; SCHIZOPHRENIA;

EID: 84866347172     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.07.039     Document Type: Article

References (53)

1. C.M. Adler, T.E. Goldberg, A.K. Malhotra, D. Pickar, and A. Breier Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers Biol. Psychiatry 43 1998 811 816
2. N.A. Anis, S.C. Berry, N.R. Burton, and D. Lodge The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate Br. J. Pharmacol. 79 1983 565 575
3. S. Attucci, V. Carla, G. Mannaioni, and F. Moroni Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges Br. J. Pharmacol. 132 2001 799 806
4. H. Awad, G.W. Hubert, Y. Smith, A.I. Levey, and P.J. Conn Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus J. Neurosci. 20 2000 7871 7879
5. J.H. Barnett, T.W. Robbins, V.C. Leeson, B.J. Sahakian, E.M. Joyce, and A.D. Blackwell Assessing cognitive function in clinical trials of schizophrenia Neurosci. Biobehav. Rev. 34 2010 1161 1177
6. J.M. Birrell, and V.J. Brown Medial frontal cortex mediates perceptual attentional set shifting in the rat J. Neurosci. 20 2000 4320 4324
7. Y. Chudasama, and T.W. Robbins Dissociable contributions of the orbitofrontal and infralimbic cortex to pavlovian autoshaping and discrimination reversal learning: further evidence for the functional heterogeneity of the rodent frontal cortex J. Neurosci. 23 2003 8771 8780
8. V.J. Collett, and G.L. Collingridge Interactions between NMDA receptors and mGlu5 receptors expressed in HEK293 cells Br. J. Pharmacol. 142 2004 991 1001
9. P.J. Conn, C.W. Lindsley, and C.K. Jones Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia Trends Pharmacol. Sci. 30 2009 25 31
10. S. Dix, G. Gilmour, S. Potts, J.W. Smith, and M. Tricklebank A within-subject cognitive battery in the rat: differential effects of NMDA receptor antagonists Psychopharmacology (Berl.) 212 2010 227 242
11. A.J. Doherty, M.J. Palmer, Z.A. Bortolotto, A. Hargreaves, A.E. Kingston, P.L. Ornstein, D.D. Schoepp, D. Lodge, and G.L. Collingridge A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices Br. J. Pharmacol. 131 2000 239 244
12. A.J. Doherty, M.J. Palmer, J.M. Henley, G.L. Collingridge, and D.E. Jane (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus Neuropharmacology 36 1997 265 267
13. S.W. Fowler, A.K. Ramsey, J.M. Walker, P. Serfozo, M.F. Olive, T.R. Schachtman, and A. Simonyi Functional interaction of mGlu5 and NMDA receptors in aversive learning in rats Neurobiol. Learn. Mem. 95 2011 73 79
14. F. Gastambide, M.C. Cotel, G. Gilmour, M.J. O'Neill, T.W. Robbins, and M.D. Tricklebank Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator Neuropsychopharmacology 37 2012 1057 1066
15. Gilmour, G.; Broad, L.M.; Wafford, K.A.; Britton, T.; Colvin, E.M.; Fivush, A.; Gastambide, F.; Getman, B.; Heinz, B.A.; McCarthy, A.P.; Prieto, L.; Shanks, E.; Smith, J.W.; Taboda, L.; Edgar, D.M.; Tricklebank, M.D. In vitro characterisation of the novel positive allosteric modulators of the mGlu5 receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology, in this issue.
16. G. Gilmour, S. Dix, L. Fellini, F. Gastambide, N. Plath, T. Steckler, J. Talpos, and M. Tricklebank NMDA receptors, cognition and schizophrenia-testing the validity of the NMDA receptor hypofunction hypothesis Neuropharmacology 62 2012 1401 1412
17. G. Gilmour, E.Y. Pioli, S.L. Dix, J.W. Smith, M.W. Conway, W.T. Jones, S. Loomis, R. Mason, S. Shahabi, and M.D. Tricklebank Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia Psychopharmacology (Berl.) 205 2009 203 216
18. L.A. Hetem, J.M. Danion, P. Diemunsch, and C. Brandt Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers Psychopharmacology (Berl.) 152 2000 283 288
19. H. Homayoun, and B. Moghaddam Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors Cereb. Cortex 16 2006 93 105
20. D.C. Javitt, and S.R. Zukin Recent advances in the phencyclidine model of schizophrenia Am. J. Psychiatry 148 1991 1301 1308
21. G.G. Kinney, M. Burno, U.C. Campbell, L.M. Hernandez, D. Rodriguez, L.J. Bristow, and P.J. Conn Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents J. Pharmacol. Exp. Ther. 306 2003 116 123
22. G.G. Kinney, J.A. O'Brien, W. Lemaire, M. Burno, D.J. Bickel, M.K. Clements, T.B. Chen, D.D. Wisnoski, C.W. Lindsley, P.R. Tiller, S. Smith, M.A. Jacobson, C. Sur, M.E. Duggan, D.J. Pettibone, P.J. Conn, and D.L. Williams Jr. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models J. Pharmacol. Exp. Ther. 313 2005 199 206
23. J.W. Kinney, C.N. Davis, I. Tabarean, B. Conti, T. Bartfai, and M.M. Behrens A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons J. Neurosci. 26 2006 1604 1615
24. L.V. Kristiansen, I. Huerta, M. Beneyto, and J.H. Meador-Woodruff NMDA receptors and schizophrenia Curr. Opin. Pharmacol. 7 2007 48 55
25. J.H. Krystal, A. Bennett, D. bi-Saab, A. Belger, L.P. Karper, D.C. D'Souza, D. Lipschitz, A. bi-Dargham, and D.S. Charney Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions Biol. Psychiatry 47 2000 137 143
26. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, J.D. Bremner, G.R. Heninger, M.B. Bowers Jr.; and D.S. Charney Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch. Gen. Psychiatry 51 1994 199 214
27. V. Labrie, and J.C. Roder The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia Neurosci. Biobehav. Rev. 34 2010 351 372
28. A.C. Lahti, H.H. Holcomb, D.R. Medoff, and C.A. Tamminga Ketamine activates psychosis and alters limbic blood flow in schizophrenia Neuroreport 6 1995 869 872
29. L. Lecourtier, H. Homayoun, G. Tamagnan, and B. Moghaddam Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex Biol. Psychiatry 62 2007 739 746
30. V.C. Leeson, T.W. Robbins, E. Matheson, S.B. Hutton, M.A. Ron, T.R. Barnes, and E.M. Joyce Discrimination learning, reversal, and set-shifting in first-episode schizophrenia: stability over six years and specific associations with medication type and disorganization syndrome Biol. Psychiatry 66 2009 586 593
31. F. Liu, S. Grauer, C. Kelley, R. Navarra, R. Graf, G. Zhang, P.J. Atkinson, M. Popiolek, C. Wantuch, X. Khawaja, D. Smith, M. Olsen, E. Kouranova, M. Lai, F. Pruthi, C. Pulicicchio, M. Day, A. Gilbert, M.H. Pausch, N.J. Brandon, C.E. Beyer, T.A. Comery, S. Logue, S. Rosenzweig-Lipson, and K.L. Marquis ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol- 5-yl]-piperidin-1- yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities J. Pharmacol. Exp. Ther. 327 2008 827 839
32. E.D. Luby, B.D. Cohen, G. Rosenbaum, J.S. Gottlieb, and R. Kelley Study of a new schizophrenomimetic drug; sernyl AMA Arch. Neurol. Psychiatry 81 1959 363 369
33. D.R. Lynch, and R.P. Guttmann Excitotoxicity: perspectives based on N-methyl-D-aspartate receptor subtypes J. Pharmacol. Exp. Ther. 300 2002 717 723
34. A.K. Malhotra, D.A. Pinals, C.M. Adler, I. Elman, A. Clifton, D. Pickar, and A. Breier Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics Neuropsychopharmacology 17 1997 141 150
35. A.K. Malhotra, D.A. Pinals, H. Weingartner, K. Sirocco, C.D. Missar, D. Pickar, and A. Breier NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers Neuropsychopharmacology 14 1996 301 307
36. G. Mannaioni, M.J. Marino, O. Valenti, S.F. Traynelis, and P.J. Conn Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function J. Neurosci. 21 2001 5925 5934
37. B. Moghaddam Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia Psychopharmacology (Berl.) 174 2004 39 44
38. J.W. Newcomer, N.B. Farber, V. Jevtovic-Todorovic, G. Selke, A.K. Melson, T. Hershey, S. Craft, and J.W. Olney Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis Neuropsychopharmacology 20 1999 106 118
39. J.W. Olney, and N.B. Farber Glutamate receptor dysfunction and schizophrenia Arch. Gen. Psychiatry 52 1995 998 1007
40. J.W. Olney, J.W. Newcomer, and N.B. Farber NMDA receptor hypofunction model of schizophrenia J. Psychiatr. Res. 33 1999 523 533
41. C.G. Parsons, W. Danysz, M. Hesselink, S. Hartmann, B. Lorenz, C. Wollenburg, and G. Quack Modulation of NMDA receptors by glycine-introduction to some basic aspects and recent developments Amino Acids 14 1998 207 216
42. A. Parwani, M.A. Weiler, T.A. Blaxton, D. Warfel, M. Hardin, K. Frey, and A.C. Lahti The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers Psychopharmacology (Berl.) 183 2005 265 274
43. A. Pisani, P. Gubellini, P. Bonsi, F. Conquet, B. Picconi, D. Centonze, G. Bernardi, and P. Calabresi Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons Neuroscience 106 2001 579 587
44. H. Rosenbrock, G. Kramer, S. Hobson, E. Koros, M. Grundl, M. Grauert, K.G. Reymann, and U.H. Schroder Functional interaction of metabotropic glutamate receptor 5 and NMDA-receptor by a metabotropic glutamate receptor 5 positive allosteric modulator Eur. J. Pharmacol. 639 2010 40 46
45. C. Schlumberger, M. Pietraszek, A. Gravius, K.U. Klein, S. Greco, L. Morè, and W. Danysz Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity Eur. J. Pharmacol. 623 2009 73 83
46. C. Schlumberger, M. Pietraszek, A. Gravius, and W. Danysz Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia Pharmacol. Biochem. Behav. 95 2010 23 30
47. J.W. Smith, F. Gastambide, G. Gilmour, S. Dix, J. Foss, K. Lloyd, N. Malik, and M. Tricklebank A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory Psychopharmacology (Berl.) 217 2011 255 269
48. M.R. Stefani, and B. Moghaddam Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade Eur. J. Pharmacol. 639 2010 26 32
49. R. Stoop, F. Conquet, B. Zuber, L.L. Voronin, and E. Pralong Activation of metabotropic glutamate 5 and NMDA receptors underlies the induction of persistent bursting and associated long-lasting changes in CA3 recurrent connections J. Neurosci. 23 2003 5634 5644
50. P.N. Vinson, and P.J. Conn Metabotropic glutamate receptors as therapeutic targets for schizophrenia Neuropharmacology 62 2012 1461 1472
51. P.L. Wood The NMDA receptor complex: a long and winding road to therapeutics IDrugs 8 2005 229 235
52. C.R. Yang, and K.A. Svensson Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia Pharmacol. Ther. 120 2008 317 332
53. M.S. Zandi, S.R. Irani, B. Lang, P. Waters, P.B. Jones, P. McKenna, A.J. Coles, A. Vincent, and B.R. Lennox Disease-relevant autoantibodies in first episode schizophrenia J. Neurol. 258 2011 686 688